These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 21047924)

  • 1. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying.
    Nicolaus M; Brödl J; Linke R; Woerle HJ; Göke B; Schirra J
    J Clin Endocrinol Metab; 2011 Jan; 96(1):229-36. PubMed ID: 21047924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia.
    Deane AM; Nguyen NQ; Stevens JE; Fraser RJ; Holloway RH; Besanko LK; Burgstad C; Jones KL; Chapman MJ; Rayner CK; Horowitz M
    J Clin Endocrinol Metab; 2010 Jan; 95(1):215-21. PubMed ID: 19892837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion.
    Witte AB; Grybäck P; Jacobsson H; Näslund E; Hellström PM; Holst JJ; Hilsted L; Schmidt PT
    Scand J Gastroenterol; 2011 Apr; 46(4):428-35. PubMed ID: 21114428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.
    Salehi M; Vahl TP; D'Alessio DA
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4909-16. PubMed ID: 18827000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.
    Schirra J; Nicolaus M; Roggel R; Katschinski M; Storr M; Woerle HJ; Göke B
    Gut; 2006 Feb; 55(2):243-51. PubMed ID: 15985560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
    Meier JJ; Gethmann A; Nauck MA; Götze O; Schmitz F; Deacon CF; Gallwitz B; Schmidt WE; Holst JJ
    Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1118-23. PubMed ID: 16403774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
    Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.
    Little TJ; Pilichiewicz AN; Russo A; Phillips L; Jones KL; Nauck MA; Wishart J; Horowitz M; Feinle-Bisset C
    J Clin Endocrinol Metab; 2006 May; 91(5):1916-23. PubMed ID: 16492694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans.
    Woerle HJ; Albrecht M; Linke R; Zschau S; Neumann C; Nicolaus M; Gerich J; Göke B; Schirra J
    Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E103-9. PubMed ID: 17971511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
    Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
    J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exenatide can reduce glucose independent of islet hormones or gastric emptying.
    Ionut V; Zheng D; Stefanovski D; Bergman RN
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E269-77. PubMed ID: 18492781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men.
    Schirra J; Kuwert P; Wank U; Leicht P; Arnold R; Göke B; Katschinski M
    Proc Assoc Am Physicians; 1997 Jan; 109(1):84-97. PubMed ID: 9010920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery.
    Svane MS; Bojsen-Møller KN; Nielsen S; Jørgensen NB; Dirksen C; Bendtsen F; Kristiansen VB; Hartmann B; Holst JJ; Madsbad S
    Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E505-14. PubMed ID: 26786780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
    Meier JJ; Kemmeries G; Holst JJ; Nauck MA
    Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of starvation and short-term refeeding on gastric emptying and postprandial blood glucose regulation in adolescent girls with anorexia nervosa.
    Heruc GA; Little TJ; Kohn MR; Madden S; Clarke SD; Horowitz M; Feinle-Bisset C
    Am J Physiol Endocrinol Metab; 2018 Oct; 315(4):E565-E573. PubMed ID: 29969316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.
    Kielgast U; Holst JJ; Madsbad S
    Diabetes; 2011 May; 60(5):1599-607. PubMed ID: 21441444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus.
    Schirra J; Leicht P; Hildebrand P; Beglinger C; Arnold R; Göke B; Katschinski M
    J Endocrinol; 1998 Jan; 156(1):177-86. PubMed ID: 9496247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
    Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
    J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial.
    Kuwata H; Iwasaki M; Shimizu S; Minami K; Maeda H; Seino S; Nakada K; Nosaka C; Murotani K; Kurose T; Seino Y; Yabe D
    Diabetologia; 2016 Mar; 59(3):453-61. PubMed ID: 26704625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.